Matthew C. Kapusta - 19 Mar 2023 Form 4 Insider Report for Decibel Therapeutics, Inc.

Role: Director
Signature: /s/ Jeffrey Schulz, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 19 Mar 2023
Net transactions value: $0
Form type: 4
Filing time: 21 Mar 2023, 16:13:38 UTC
Previous filing: 09 Mar 2023
Next filing: 25 Sep 2023
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	DBTX	Common Stock	Award	$0	+10,000		$0.000000	10,000	19 Mar 2023	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	DBTX	Stock Options (right to buy)	Award	$0	+10,000		$0.000000	10,000	19 Mar 2023	Common Stock	10,000	$3.34	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Consists of shares of the Issuer's common stock issuable under 10,000 restricted stock units ("RSUs"). Each RSU represents the right to receive one share of the Issuer's common stock upon vesting. The RSUs are scheduled to vest in equal annual installments until the third anniversary of the grant date, subject to the reporting person's continued service.
F2	Includes 10,000 unvested RSUs. Each unvested RSU represents the right to receive one share of the Issuer's common stock upon vesting.
F3	The option was granted on March 19, 2023. The shares underlying the option vest in equal monthly installments until the third anniversary of the grant date, subject to the reporting person's continued service.